Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PCI Announces Capital Investment in Rockford Facilities

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Leading pharmaceutical packaging firm investing in support of business growth.

Packaging Coordinators Inc (PCI) has announced further investment in its Rockford facilities in support of business growth and expansion.

The company acquired AndersonBrecon Inc. in May of this year and is adding additional equipment capacity and facilities infrastructure through capital investment, as well as hiring in support of business growth.

The company provides packaging services for pharmaceutical and healthcare products, working with leading Pharmaceutical and Biotech companies to bring lifesaving medicines to patients.

PCI operates 9 facilities in the greater Rockford, Illinois area totaling over 1 million square feet and employing over 1,300 highly trained associates.

PCI is owned by an entity formed by affiliates of lead investor Frazier Healthcare, a leading provider of growth equity and venture capital to high growth and emerging healthcare service and Biotech companies.

Continued Growth and Expansion
PCI’s Rockford location is experiencing its fourth straight year of significant growth. The company is experiencing substantial growth in 2013, which is anticipated to continue in 2014 and beyond.

In support of this growth, PCI has hired approximately 160 associates since January of 2012. Positions added include hourly, skilled labor, as well as management.

In addition to hiring, the company is looking to support new business by expanding its machine capacity, warehousing, and facilities infrastructure. PCI has added multiple blister packaging and bottling lines to meet increased demand in Ethical (prescription) and Over-the-Counter pharmaceutical markets and plans additional investment in this area.

The company is also investing in support of growth markets including commercial Biotech medicines and Clinical (Investigational) medicines.

Capital investments include expansion of on-site refrigerated Cold Chain storage capacity at 2 – 8° Celsius, -20° Celsius, and -80° Celsius.

A History Of Investment
The company opened a stand-alone potent compound packaging facility in 2010 and a new Clinical (Investigational) medicines packaging facility in 2011.

PCI’s largest Rockford facility, located at the Greater Rockford Industrial Park, was most recently expanded in 2008 and comprises over 720,000 square feet.

PCI’s North American and European sites feature state-of-the-art packaging facilities and cutting edge technologies, supporting very recognizable brands in the global healthcare market.

The company packages medicines destined for patients spanning over 100 countries across the globe. PCI’s headquarters in Philadelphia, PA employs approximately 475 associates.

A facility in Woodstock, IL employs approximately 125 additional associates. PCI’s domestic locations are complemented by four packaging sites in Wales, which currently employ approximately 300 associates, mainly in support of pharmaceutical products for the European region.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PCI Announces Definitive Agreement to Acquire Penn Pharma
PCI’s expands service offering with acquisition of Penn Pharma.
Thursday, July 31, 2014
Peter Belden Named General Manager of PCI Rockford Facilities
Belden returns to PCI North America to manage Rockford, IL operations.
Monday, September 02, 2013
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!